Floatz logo

Di-Leu16-Il2

Recurrent Adult Grade III Lymphomatoid Granulomatosis

City of Hope Medical Centerprotein_peptidePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Adult Grade III Lymphomatoid Granulomatosis cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University of Chicago
Phase 2BBB
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

Di-Leu16-Il2 is also rated in:

anaplastic large cell lymphomaDormant
C
Indicative ·
38 / 100
View asset →
primary cutaneous B-cell lymphomaDormant
C
Indicative ·
38 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →